KalVista Pharmaceuticals (KALV) Competitors $11.32 +0.23 (+2.07%) Closing price 04:00 PM EasternExtended Trading$11.10 -0.22 (-1.94%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV vs. IBRX, BEAM, VCEL, MIRM, GMTX, EWTX, CNTA, KYMR, CGON, and DNLIShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include ImmunityBio (IBRX), Beam Therapeutics (BEAM), Vericel (VCEL), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Edgewise Therapeutics (EWTX), Centessa Pharmaceuticals (CNTA), Kymera Therapeutics (KYMR), CG Oncology (CGON), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. ImmunityBio Beam Therapeutics Vericel Mirum Pharmaceuticals Gemini Therapeutics Edgewise Therapeutics Centessa Pharmaceuticals Kymera Therapeutics CG Oncology Denali Therapeutics ImmunityBio (NASDAQ:IBRX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the MarketBeat Community prefer IBRX or KALV? KalVista Pharmaceuticals received 332 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 75.00% of users gave KalVista Pharmaceuticals an outperform vote while only 43.24% of users gave ImmunityBio an outperform vote. CompanyUnderperformOutperformImmunityBioOutperform Votes1643.24% Underperform Votes2156.76% KalVista PharmaceuticalsOutperform Votes34875.00% Underperform Votes11625.00% Does the media favor IBRX or KALV? In the previous week, ImmunityBio and ImmunityBio both had 7 articles in the media. ImmunityBio's average media sentiment score of 0.48 beat KalVista Pharmaceuticals' score of 0.38 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral KalVista Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend IBRX or KALV? ImmunityBio currently has a consensus price target of $12.19, suggesting a potential upside of 310.35%. KalVista Pharmaceuticals has a consensus price target of $24.83, suggesting a potential upside of 119.38%. Given ImmunityBio's higher possible upside, research analysts clearly believe ImmunityBio is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has more risk & volatility, IBRX or KALV? ImmunityBio has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Do insiders and institutionals hold more shares of IBRX or KALV? 8.6% of ImmunityBio shares are held by institutional investors. 83.4% of ImmunityBio shares are held by insiders. Comparatively, 10.5% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is IBRX or KALV more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-8,016.83% N/A -110.02% KalVista Pharmaceuticals N/A -103.92%-88.06% Which has higher valuation and earnings, IBRX or KALV? KalVista Pharmaceuticals has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.75M171.90-$583.20M-$0.63-4.71KalVista PharmaceuticalsN/AN/A-$126.64M-$3.72-3.04 SummaryImmunityBio and KalVista Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$562.79M$6.73B$5.55B$7.50BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-3.117.0222.9418.10Price / SalesN/A199.21361.5886.56Price / CashN/A65.6738.1634.64Price / Book2.335.926.494.00Net Income-$126.64M$142.59M$3.21B$247.18M7 Day Performance-8.27%-9.09%-6.28%-6.34%1 Month Performance4.14%-10.07%-0.55%-7.34%1 Year Performance0.53%-14.92%6.18%-4.21% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals4.1533 of 5 stars$11.32+2.1%$24.83+119.4%+0.5%$562.79MN/A-3.11100High Trading VolumeIBRXImmunityBio1.9817 of 5 stars$2.85+5.2%$12.19+327.6%-42.1%$2.43B$14.75M-3.10590Analyst ForecastGap DownBEAMBeam Therapeutics3.1495 of 5 stars$24.01+3.0%$50.82+111.7%-39.5%$2.40B$63.52M-13.64510Short Interest ↑Gap DownVCELVericel3.1245 of 5 stars$47.94+3.6%$62.29+29.9%-13.6%$2.40B$237.22M799.13300Positive NewsGap DownMIRMMirum Pharmaceuticals4.3341 of 5 stars$47.02flat$58.20+23.8%+78.5%$2.30B$336.89M-23.28140Positive NewsGMTXGemini TherapeuticsN/A$52.24-1.9%N/A+37.8%$2.26BN/A-52.2430High Trading VolumeEWTXEdgewise Therapeutics1.8921 of 5 stars$23.37-1.0%$45.38+94.2%-12.2%$2.22BN/A-15.5860Analyst ForecastOptions VolumeNews CoverageGap DownCNTACentessa Pharmaceuticals2.8734 of 5 stars$16.63+5.6%$26.00+56.3%+20.9%$2.19B$6.85M-10.87200Analyst ForecastAnalyst RevisionGap DownKYMRKymera Therapeutics1.302 of 5 stars$33.70+3.6%$56.36+67.2%-30.0%$2.19B$47.07M-14.40170News CoverageGap DownCGONCG Oncology1.1537 of 5 stars$28.53+5.5%$63.88+123.9%-45.1%$2.17B$684,000.000.0061Analyst ForecastAnalyst RevisionNews CoverageGap DownDNLIDenali Therapeutics4.2325 of 5 stars$14.76+2.3%$37.20+152.0%-29.1%$2.14B$330.53M-5.35430News CoverageGap Down Remove Ads Related Companies and Tools Related Companies IBRX Alternatives BEAM Alternatives VCEL Alternatives MIRM Alternatives GMTX Alternatives EWTX Alternatives CNTA Alternatives KYMR Alternatives CGON Alternatives DNLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALV) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
